Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Yue, Zhenyu ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic mouse models; Lrrk2; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CYTOSKELETON PROTEIN; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CELL FUNCTION; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; GENETIC MODEL; MISSENSE MUTATION; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SYNAPSE VESICLE; TAUOPATHY; TRANSGENIC MOUSE;

EID: 84858696035     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70056-6     Document Type: Article

References (20)

1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron 2004;44:595-600.
2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron 2004;44:601-7.
3. West AB, Moore DJ, Biskup S, Bugayenko A, SmithWW, Ross CA, et al Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc Natl Acad Sci U S A 2005;102:16842-7
4. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study, Lancet Neurol 2008;7:583-90.
5. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010;16:237-42.
6. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231-3.
7. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007;46:1380-8.
8. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16:223-32.
9. Yue Z. LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles, FEBS J 2009;276:6445-54.
10. Heintz N. BAC to the future: the use of bac transgenic mice for neuroscience research. Nat Rev Neurosci 2001;2:861-70.
11. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010;30:1788-97.
12. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006;67:1506-8.
13. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010;11:791-7.
14. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-22.
15. Yue Z, Lachenmayer ML. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord.
16. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-12.
17. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson'sdisease-related mutant alpha-synuclein. Neuron 2009;64:807-27.
18. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher 3rd RJ, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 2010;107:9879-84.
19. Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, et al. Phosphorylationdependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 2011;6:e17153.
20. Goldstein DS, Imrich R, Peckham E, Holmes C, Lopez G, Crews C, et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation, Neurology 2007;69:1580-4.